Change Of Neurotrophic Factors In Ketamine Abusers And Its Implication In Addiction Therapy | 30497
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2384

Journal of Addiction Research & Therapy received 2384 citations as per google scholar report

Journal of Addiction Research & Therapy peer review process verified at publons
Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • SafetyLit
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Change of neurotrophic factors in Ketamine abusers and its implication in addiction therapy

4th International Conference and Exhibition on Addiction Research & Therapy

Ni Fan

Posters-Accepted Abstracts: J Addict Res Ther

DOI: 10.4172/2155-6105.S1.022

Brain-derived neurotrophic factor (BDNF) is an important neurotrophic factor associated with cognitive function, learning and memory as well as synaptic plasticity. Nerve growth factor (NGF) is widely distributed in vivo. NGF may play an important role in promoting the development of the nervous system; maintaining neuronal growth, survival and differentiation; and influencing synaptic plasticity. We investigated the serum levels of BDNF and NGF in a group of chronic ketamine abusers in comparison to healthy controls. The correlations between the serums BDNF, NGF level with the subjects’ demographic, pattern of ketamine use were also examined. 93 subjects who met the criteria of ketamine dependence and 39 healthy subjects were recruited. Serum BDNF and NGF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). We found both serum levels of BDNF and NGF were significant lower in the ketamine users compared to the healthy control subjects (9.50±6.68 versus 14.37±6.07 ng/ml, p=0.019 for BDNF; 1.93±0.80 versus 2.60±1.07 ng/ml, p=0.011 for NGF). BDNF level was negatively associated with current frequency of ketamine use (r=−0.209, p=0.045). BDNF and NGF may play a role in chronic ketamine related symptoms and may possibly serve as potential approach for therapy.

Ni Fan, MD completed her PhD from Louisiana State University Health Science Center at 2009 and continued her Post-doc training at Yale University School of Medicine from 2009 to 2012. Currently, she is the Vice Director of the Psychiatric Research Institute of Guangzhou Brain Hospital, the Affiliated Brain Hospital of Guangzhou Medical University. Her research was funded by National Nature Science Foundation of China.